Naimish Patel
CIK: 0002021679
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Oct 26, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectRestricted Stock Units
12K shares- - Oct 26, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
24K shares- - Sep 11, 2026AGMB
AgomAb Therapeutics NV
Award(A)DirectStock Option (Right to Buy)
56.3K shares- - May 29, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectRestricted Stock Units
22K shares- - May 29, 2026CRSP
CRISPR Therapeutics AG
Sale(S)Direct3.8K shares at avg. $55.62$211K - May 28, 2026CRSP
CRISPR Therapeutics AG
Exercise(M)Direct10K shares- - Mar 20, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
38.5K shares- - Mar 20, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectRestricted Stock Units
30K shares- - Mar 16, 2026CRSP
CRISPR Therapeutics AG
Sale(S)Direct3.2K shares at avg. $48.26$152K - Mar 14, 2026CRSP
CRISPR Therapeutics AG
Exercise(M)Direct8.1K shares- - Oct 3, 2025CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
16.5K shares- - May 30, 2025CRSP
CRISPR Therapeutics AG
Award(A)DirectRestricted Stock Units
25K shares- - May 29, 2025CRSP
CRISPR Therapeutics AG
Sale(S)Direct3.9K shares at avg. $35.94$141K - May 28, 2025CRSP
CRISPR Therapeutics AG
Exercise(M)Direct10K shares- - Apr 3, 2025CRSP
CRISPR Therapeutics AG
Purchase(P)Direct1.5K shares at avg. $32.96$50K - Mar 14, 2025CRSP
CRISPR Therapeutics AG
Award(A)DirectRestricted Stock Units
32.5K shares- - Mar 14, 2025CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
46.7K shares- - Oct 16, 2024CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
18.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 26, 2026 |  CRSP CRISPR Therapeutics AG | Award(A) Restricted Stock Units | 12,000 | - | - | Direct |
| Oct 26, 2026 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 24,000 | - | - | Direct |
| Sep 11, 2026 |  AGMB AgomAb Therapeutics NV | Award(A) Stock Option (Right to Buy) | 56,328 | - | - | Direct |
| May 29, 2026 | CRSP CRISPR Therapeutics AG | Award(A) Restricted Stock Units | 22,000 | - | - | Direct |
| May 29, 2026 | CRSP CRISPR Therapeutics AG | Sale(S) | 3,786 | $55.62 | $210,577 | Direct |
| May 28, 2026 | CRSP CRISPR Therapeutics AG | Exercise(M) | 10,000 | - | $0 | Direct |
| Mar 20, 2026 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 38,499 | - | - | Direct |
| Mar 20, 2026 | CRSP CRISPR Therapeutics AG | Award(A) Restricted Stock Units | 30,000 | - | - | Direct |
| Mar 16, 2026 | CRSP CRISPR Therapeutics AG | Sale(S) | 3,150 | $48.26 | $152,019 | Direct |
| Mar 14, 2026 | CRSP CRISPR Therapeutics AG | Exercise(M) | 8,125 | - | $0 | Direct |
| Oct 3, 2025 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 16,500 | - | - | Direct |
| May 30, 2025 | CRSP CRISPR Therapeutics AG | Award(A) Restricted Stock Units | 25,000 | - | - | Direct |
| May 29, 2025 | CRSP CRISPR Therapeutics AG | Sale(S) | 3,932 | $35.94 | $141,316 | Direct |
| May 28, 2025 | CRSP CRISPR Therapeutics AG | Exercise(M) | 10,000 | - | - | Direct |
| Apr 3, 2025 | CRSP CRISPR Therapeutics AG | Purchase(P) | 1,508 | $32.96 | $49,704 | Direct |
| Mar 14, 2025 | CRSP CRISPR Therapeutics AG | Award(A) Restricted Stock Units | 32,500 | - | - | Direct |
| Mar 14, 2025 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 46,667 | - | - | Direct |
| Oct 16, 2024 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 18,333 | - | - | Direct |
1-18 of 18 transactions
About Patel Naimish
Patel Naimish (SEC CIK 0002021679) files insider reports with the SEC as Chief Medical Officer of CRISPR Therapeutics AG (CRSP) and Director of AgomAb Therapeutics NV (AGMB).
Signal8 holds 13 ownership filings by Patel Naimish (1 Form 3, 12 Form 4), filed between Oct 18, 2024 and Oct 28, 2026. Those filings report 18 transactions, from Oct 16, 2024 to Oct 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Patel Naimish's filings is in BOSTON, MA.
Recent filings by Patel Naimish
- Oct 26, 2026: Grants or awards of CRSP derivative securities (2 lines, Form 4, code A).
- Sep 11, 2026: Grant or award of AGMB derivative securities (Form 4, code A).
- May 29, 2026: Grant or award of CRSP derivative securities (Form 4, code A).
- May 29, 2026: Open-market sale of CRSP shares (Form 4, code S).
- May 28, 2026: Option exercise of CRSP shares (Form 4, code M).
Other insiders filing for CRISPR Therapeutics AG (CRSP)
- Sakhamuri Sivakesava, Chief Technical Officer
- Silver Andrew Jacob, Chief Financial Officer
- KASINGER JAMES R., General Counsel and Secretary
- Kulkarni Samarth, Chief Executive Officer
- George Simeon, Director
- Behbahani Ali, Director